The role of the complement system in acute kidney injury

Seminars in Nephrology

Volumn 33, Issue 6, 2013, Pages 543-556

  McCullough, James W ^a   Renner, Brandon ^a   Thurman, Joshua M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Complement; Ischemia reperfusion

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANAPHYLATOXIN; CD59 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C6; DECAY ACCELERATING FACTOR; ECULIZUMAB; MIROCOCEPT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; DELAYED GRAFT FUNCTION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; INNATE IMMUNITY; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PREVENTION STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ACUTE KIDNEY INJURY; COMPLEMENT; ISCHEMIA/REPERFUSION;

ACUTE KIDNEY INJURY; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; HUMANS; INFLAMMATION; ISCHEMIA; KIDNEY; REPERFUSION INJURY;

EID: 84886312055     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.08.005     Document Type: Article

References (124)

1. Bonventre J.V., Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011, 121:4210-4221.
2. Schrier R.W., Wang W., Poole B., Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004, 114:5-14.
3. Singbartl K., Kellum J.A. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012, 81:819-825.
4. Schrier R.W., Wang W. Acute renal failure and sepsis. N Engl J Med 2004, 351:159-169.
5. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
6. Xiao H., Schreiber A., Heeringa P., Falk R.J., Jennette J.C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007, 170:52-64.
7. Quigg R.J., He C., Lim A., Berthiaume D., Alexander J.J., Kraus D., et al. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med 1998, 188:1321-1331.
8. Thurman J.M., Ljubanovic D., Edelstein C.L., Gilkeson G.S., Holers V.M. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003, 170:1517-1523.
9. Bonventre J.V., Zuk A. Ischemic acute renal failure: an inflammatory disease?. Kidney Int 2004, 66:480-485.
10. Daemen M.A., van't Veer C., Wolfs T.G., Buurman W.A. Ischemia/reperfusion-induced IFN-gamma up-regulation: involvement of IL-12 and IL-18. J Immunol 1999, 162:5506-5510.
11. Hoke T.S., Douglas I.S., Klein C.L., He Z., Fang W., Thurman J.M., et al. Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol 2007, 18:155-164.
12. Goes N., Urmson J., Ramassar V., Halloran P.F. Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995, 59:565-572.
13. Li L., Okusa M.D. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol 2010, 30:268-277.
14. Rabb H., Daniels F., O'Donnell M., Haq M., Saba S.R., Keane W., et al. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol 2000, 279:F525-F531.
15. Thurman J.M., Lenderink A.M., Royer P.A., Coleman K.E., Zhou J., Lambris J.D., et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol 2007, 178:1819-1828.
16. Cunningham P.N., Wang Y., Guo R., He G., Quigg R.J. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol 2004, 172:2629-2635.
17. Leemans J.C., Stokman G., Claessen N., Rouschop K.M., Teske G.J., Kirschning C.J., et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005, 115:2894-2903.
18. Wu H., Chen G., Wyburn K.R., Yin J., Bertolino P., Eris J.M., et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007, 117:2847-2859.
19. Kramer A.A., Postler G., Salhab K.F., Mendez C., Carey L.C., Rabb H. Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability. Kidney Int 1999, 55:2362-2367.
20. Anderson J., Fleming S.D., Rehrig S., Tsokos G.C., Basta M., Shea-Donohue T. Intravenous immunoglobulin attenuates mesenteric ischemia-reperfusion injury. Clin Immunol 2005, 114:137-146.
21. Chan R.K., Ibrahim S.I., Takahashi K., Kwon E., McCormack M., Ezekowitz A., et al. The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion. J Immunol 2006, 177:8080-8085.
22. Thurman J.M., Lucia M.S., Ljubanovic D., Holers V.M. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005, 67:524-530.
23. Stein J.H., Osgood R.W., Barnes J.L., Reineck H.J., Pinckard R.N., McManus L.M. The role of complement in the pathogenesis of postischemic acute renal failure. Miner Electrolyte Metab 1985, 11:256-261.
24. Renner B., Strassheim D., Amura C.R., Kulik L., Ljubanovic D., Glogowska M.J., et al. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 2010, 185:4393-4400.
25. Nath K.A., Hostetter M.K., Hostetter T.H. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985, 76:667-675.
26. Isenman D.E., Kells D.I., Cooper N.R., Muller-Eberhard H.J., Pangburn M.K. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 1981, 20:4458-4467.
27. Peake P.W., Pussell B.A., Mackinnon B., Charlesworth J.A. The effect of pH and nucleophiles on complement activation by human proximal tubular epithelial cells. Nephrol Dial Transplant 2002, 17:745-752.
28. Carroll M.C., Holers V.M. Innate autoimmunity. Adv Immunol 2005, 86:137-157.
29. Elward K., Griffiths M., Mizuno M., Harris C.L., Neal J.W., Morgan B.P., et al. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 2005, 280:36342-36354.
30. Kulik L., Fleming S.D., Moratz C., Reuter J.W., Novikov A., Chen K., et al. Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol 2009, 182:5363-5373.
31. Zhang M., Alicot E.M., Chiu I., Li J., Verna N., Vorup-Jensen T., et al. Identification of the target self-antigens in reperfusion injury. J Exp Med 2006, 203:141-152.
32. Fleming S.D., Shea-Donohue T., Guthridge J.M., Kulik L., Waldschmidt T.J., Gipson M.G., et al. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 2002, 169:2126-2133.
33. Weiser M.R., Williams J.P., Moore F.D., Kobzik L., Ma M., Hechtman H.B., et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996, 183:2343-2348.
34. Zhou W., Farrar C.A., Abe K., Pratt J.R., Marsh J.E., Wang Y., et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000, 105:1363-1371.
35. Lin T., Zhou W., Farrar C.A., Hargreaves R.E., Sheerin N.S., Sacks S.H. Deficiency of C4 from donor or recipient mouse fails to prevent renal allograft rejection. Am J Pathol 2006, 168:1241-1248.
36. Park P., Haas M., Cunningham P.N., Bao L., Alexander J.J., Quigg R.J. Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol Renal Physiol 2002, 282:F352-F357.
37. Collard C.D., Montalto M.C., Reenstra W.R., Buras J.A., Stahl G.L. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001, 159:1045-1054.
38. de Vries B., Walter S.J., Peutz-Kootstra C.J., Wolfs T.G., van Heurn L.W., Buurman W.A. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004, 165:1677-1688.
39. Castellano G., Melchiorre R., Loverre A., Ditonno P., Montinaro V., Rossini M., et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol 2010, 176:1648-1659.
40. Schwaeble W.J., Lynch N.J., Clark J.E., Marber M., Samani N.J., Ali Y.M., et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2011, 108:7523-7528.
41. Moller-Kristensen M., Wang W., Ruseva M., Thiel S., Nielsen S., Takahashi K., et al. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol 2005, 61:426-434.
42. Thurman J.M., Holers V.M. The central role of the alternative complement pathway in human disease. J Immunol 2006, 176:1305-1310.
43. Pangburn M.K., Schreiber R.D., Muller-Eberhard H.J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 1981, 154:856-867.
44. Pangburn M.K., Muller-Eberhard H.J. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann N Y Acad Sci 1983, 421:291-298.
45. Bexborn F., Andersson P.O., Chen H., Nilsson B., Ekdahl K.N. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 2008, 45:2370-2379.
46. Law S.K., Dodds A.W. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997, 6:263-274.
47. Sahu A., Kozel T.R., Pangburn M.K. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J 1994, 302:429-436.
48. Nickeleit V., Zeiler M., Gudat F., Thiel G., Mihatsch M.J. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002, 13:242-251.
49. Zwirner J., Felber E., Herzog V., Riethmuller G., Feucht H.E. Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int 1989, 36:1069-1077.
50. Varis J., Rantala I., Pasternack A., Oksa H., Jantti M., Paunu E.S., et al. Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 1993, 46:607-610.
51. Arnold J.N., Dwek R.A., Rudd P.M., Sim R.B. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 2006, 106:103-110.
52. Arnold J.N., Wormald M.R., Suter D.M., Radcliffe C.M., Harvey D.J., Dwek R.A., et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem 2005, 280:29080-29087.
53. McMullen M.E., Hart M.L., Walsh M.C., Buras J., Takahashi K., Stahl G.L. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 2006, 211:759-766.
54. Riley-Vargas R.C., Lanzendorf S., Atkinson J.P. Targeted and restricted complement activation on acrosome-reacted spermatozoa. J Clin Invest 2005, 115:1241-1249.
55. Gershov D., Kim S., Brot N., Elkon K.B. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000, 192:1353-1364.
56. Trouw L.A., Bengtsson A.A., Gelderman K.A., Dahlback B., Sturfelt G., Blom A.M. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007, 282:28540-28548.
57. Schreiber R.D., Pangburn M.K., Lesavre P.H., Muller-Eberhard H.J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A 1978, 75:3948-3952.
58. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 2007, 179:2600-2608.
59. Kimura Y., Zhou L., Miwa T., Song W.C. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J Clin Invest 2010, 120:3545-3554.
60. Gaarkeuken H., Siezenga M.A., Zuidwijk K., van Kooten C., Rabelink T.J., Daha M.R., et al. Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol 2008, 295:F1397-F1403.
61. Miwa T., Sato S., Gullipalli D., Nangaku M., Song W.C. Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice. J Immunol 2013, 190:3552-3559.
62. Brooimans R.A., Stegmann A.P., van Dorp W.T., van der Ark A.A., van der Woude F.J., van Es L.A., et al. Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J Clin Invest 1991, 88:379-384.
63. Gerritsma J.S., van Kooten C., Gerritsen A.F., van Es L.A., Daha M.R. Transforming growth factor-beta 1 regulates chemokine and complement production by human proximal tubular epithelial cells. Kidney Int 1998, 53:609-616.
64. Welch T.R., Beischel L.S., Frenzke M., Witte D. Regulated expression of complement factor B in the human kidney. Kidney Int 1996, 50:521-525.
65. Takada M., Nadeau K.C., Shaw G.D., Marquette K.A., Tilney N.L. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997, 99:2682-2690.
66. Farrar C.A., Zhou W., Lin T., Sacks S.H. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006, 20:217-226.
67. Pratt J.R., Basheer S.A., Sacks S.H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002, 8:582-587.
68. Naesens M., Li L., Ying L., Sansanwal P., Sigdel T.K., Hsieh S.C., et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 2009, 20:1839-1851.
69. Damman J., Nijboer W.N., Schuurs T.A., Leuvenink H.G., Morariu A.M., Tullius S.G., et al. Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant 2011, 26:2345-2354.
70. Chenoweth D.E., Cheung A.K., Henderson L.W. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1983, 24:764-769.
71. Schulman G., Fogo A., Gung A., Badr K., Hakim R. Complement activation retards resolution of acute ischemic renal failure in the rat. Kidney Int 1991, 40:1069-1074.
72. Schiffl H., Lang S.M., Konig A., Strasser T., Haider M.C., Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994, 344:570-572.
73. Gutierrez A., Alvestrand A., Bergstrom J., Beving H., Lantz B., Henderson L.W. Biocompatibility of hemodialysis membranes: a study in healthy subjects. Blood Purif 1994, 12:95-105.
74. Mulvihill J., Crost T., Renaux J.L., Cazenave J.P. Evaluation of haemodialysis membrane biocompatibility by parallel assessment in an ex vivo model in healthy volunteers. Nephrol Dial Transplant 1997, 12:1968-1973.
75. Ichida S., Yuzawa Y., Okada H., Yoshioka K., Matsuo S. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994, 46:89-96.
76. Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int 1998, 54:1419-1428.
77. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009, 9:729-740.
78. Alexander J.J., Quigg R.J. The simple design of complement factor H: looks can be deceiving. Mol Immunol 2006, 44:123-132.
79. Pickering M.C., Cook H.T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008, 151:210-230.
80. Thurman J.M., Renner B. Dynamic control of the complement system by modulated expression of regulatory proteins. Lab Invest 2011, 91:4-11.
81. Barilla-LaBarca M.L., Liszewski M.K., Lambris J.D., Hourcade D., Atkinson J.P. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol 2002, 168:6298-6304.
82. Renner B., Coleman K., Goldberg R., Amura C., Holland-Neidermyer A., Pierce K., et al. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 2010, 185:3086-3094.
83. Thurman J.M., Ljubanovic D., Royer P.A., Kraus D.M., Molina H., Barry N.P., et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006, 116:357-368.
84. Bao L., Wang Y., Chang A., Minto A.W., Zhou J., Kang H., et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 2007, 18:811-822.
85. Nomura A., Nishikawa K., Yuzawa Y., Okada H., Okada N., Morgan B.P., et al. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest 1995, 96:2348-2356.
86. Renner B., Ferreira V.P., Cortes C., Goldberg R., Ljubanovic D., Pangburn M.K., et al. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 2011, 80:165-173.
87. Sellier-Leclerc A.L., Fremeaux-Bacchi V., Dragon-Durey M.A., Macher M.A., Niaudet P., Guest G., et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007, 18:2392-2400.
88. Zuber J., Quintrec M.L., Krid S., Bertoye C., Gueutin V., Lahoche A., et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012, 12:3337-3354.
89. Yamada K., Miwa T., Liu J., Nangaku M., Song W.C. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004, 172:3869-3875.
90. Mulligan M.S., Schmid E., Beck-Schimmer B., Till G.O., Friedl H.P., Brauer R.B., et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996, 98:503-512.
91. Huey R., Bloor C.M., Kawahara M.S., Hugli T.E. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol 1983, 112:48-60.
92. Zwirner J., Fayyazi A., Gotze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999, 36:877-884.
93. Fayyazi A., Scheel O., Werfel T., Schweyer S., Oppermann M., Gotze O., et al. The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology 2000, 99:38-45.
94. Foreman K.E., Vaporciyan A.A., Bonish B.K., Jones M.L., Johnson K.J., Glovsky M.M., et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994, 94:1147-1155.
95. Zahedi R., Braun M., Wetsel R.A., Ault B.H., Khan A., Welch T.R., et al. The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin Exp Immunol 2000, 121:226-233.
96. De Vries B., Matthijsen R.A., Wolfs T.G., Van Bijnen A.A., Heeringa P., Buurman W.A. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003, 75:375-382.
97. Peng Q., Li K., Smyth L.A., Xing G., Wang N., Meader L., et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol 2012, 23:1474-1485.
98. Braun M.C., Reins R.Y., Li T.B., Hollmann T.J., Dutta R., Rick W.A., et al. Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 2004, 173:4190-4196.
99. Bao L., Osawe I., Haas M., Quigg R.J. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 2005, 175:1947-1955.
100. Tang Z., Lu B., Hatch E., Sacks S.H., Sheerin N.S. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 2009, 20:593-603.
101. Papadimitriou J.C., Ramm L.E., Drachenberg C.B., Trump B.F., Shin M.L. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J Immunol 1991, 147:212-217.
102. Burger A., Wagner C., Hug F., Hansch G.M. Up-regulation of intracellular calcium, cyclic adenosine monophosphate and fibronectin synthesis in tubuar epithelial cells by complement. Eur J Immunol 1999, 29:1188-1193.
103. Dobrina A., Pausa M., Fischetti F., Bulla R., Vecile E., Ferrero E., et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 2002, 99:185-192.
104. Tedesco F., Pausa M., Nardon E., Introna M., Mantovani A., Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997, 185:1619-1627.
105. Sahu A., Lambris J.D. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 2001, 180:35-48.
106. Sim R.B., Malhotra V., Day A.J., Erdei A. Structure and specificity of complement receptors. Immunol Lett 1987, 14:183-190.
107. Marks R.M., Todd R.F., Ward P.A. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 1989, 339:314-317.
108. Videm V., Strand E. Changes in neutrophil surface-receptor expression after stimulation with FMLP, endotoxin, interleukin-8 and activated complement compared to degranulation. Scand J Immunol 2004, 59:25-33.
109. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350.
110. Damman J., Schuurs T.A., Ploeg R.J., Seelen M.A. Complement and renal transplantation: from donor to recipient. Transplantation 2008, 85:923-927.
111. Le Quintrec M., Zuber J., Moulin B., Kamar N., Jablonski M., Lionet A., et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013, 13:663-675.
112. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nat Biotechnol 2007, 25:1265-1275.
113. Arumugam T.V., Shiels I.A., Strachan A.J., Abbenante G., Fairlie D.P., Taylor S.M. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003, 63:134-142.
114. De Vries B., Kohl J., Leclercq W.K., Wolfs T.G., Van Bijnen A.A., Heeringa P., et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003, 170:3883-3889.
115. Thurman J.M., Royer P.A., Ljubanovic D., Dursun B., Lenderink A.M., Edelstein C.L., et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 2006, 17:707-715.
116. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M.F., et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249:146-151.
117. Park P., Haas M., Cunningham P.N., Alexander J.J., Bao L., Guthridge J.M., et al. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol 2001, 12:1383-1390.
118. Quigg R.J., Kozono Y., Berthiaume D., Lim A., Salant D.J., Weinfeld A., et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998, 160:4553-4560.
119. Atkinson C., Song H., Lu B., Qiao F., Burns T.A., Holers V.M., et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005, 115:2444-2453.
120. Huang Y., Qiao F., Atkinson C., Holers V.M., Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008, 181:8068-8076.
121. Song H., He C., Knaak C., Guthridge J.M., Holers V.M., Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 2003, 111:1875-1885.
122. Pratt J.R., Jones M.E., Dong J., Zhou W., Chowdhury P., Smith R.A., et al. Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol 2003, 163:1457-1465.
123. Palevsky P.M., Molitoris B.A., Okusa M.D., Levin A., Waikar S.S., Wald R., et al. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol 2012, 7:844-850.
124. Zuber J., Fakhouri F., Roumenina L.T., Loirat C., Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643-657.